CLINICAL ASSESSMENT OF TAXANES IN THE FIRST-LINE CYTOTOXIC THERAPY OF CASTRATION-RESISTANT PROSTATE CANCER
https://doi.org/10.21518/2079-701X-2016-10-20-23
Abstract
The article tells about the current problems in the treatment of castrate-resistant prostate cancer. An extensive search for more effective treatments resulted in the development of a number of novel drugs which affect the quality of life of patients as well as increase the overall survival rate and time to PSA progression. The article studied the clinical efficacy of first-line cytotoxic chemotherapy with docetaxel. Satisfactory tolerance of docetaxel monotherapy was demonstrated. PSA levels declined > 50% in 43.7% of patients with overall survival up to 16 months.
About the Authors
A. A. GRITSKEVICH
Vishnevsky Institute of Surgery
Russian Federation
Russian Federation
PhD in medicine
Moscow
S. V. MISHUGIN
City Clinical Hospital №57
Russian Federation
Russian Federation
PhD in medicine
Moscow
A. A. TEPLOV
Vishnevsky Institute of Surgery
Russian Federation
Russian Federation
MD, Prof.
Moscow
I. G. RUSAKOV
City Clinical Hospital №57
Russian Federation
Russian Federation
MD, Prof.
Moscow
References
1. Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2014 году. М., 2016: 9-145. / Kaprin A.D., Starinskiy V.V., Petrova G.V. Malignancies in Russia in 2014. M., 2016: 9-145.
2. Pagliarulo V et al. Contemporary role of androgen deprivation therapy for prostate cancer. Eur. Urol., 2012, 61: 11-25.
3. Center MM, Jemal A, Lortet-Tieulent J. International variation in prostate cancer incidence and mortality rates. European Urology, 2012 Jun, 61(6): 53-66.
4. Алексеев Б.Я., Андрианов А.Н. Возможности и механизмы действия гормональной терапии у больных кастрационно-резистентным раком предстательной железы. Онкоурология, 2013, 1: 34-43. / Alekseev B.Y., Andrianov A.N. Prospects and mechanisms of action of hormone therapy in patients with castrationresistant prostate cancer. Onkourologiya, 2013, 1: 34-43.
5. Heidenreich A, Bolla M, Joniau S, van der Kwast TH, Matveev V, Mason MD, Mottet N, Schmid H-P, Wiegel T, Zattoni F. Recommendations for the treatment of prostate cancer. European Association of urology, 2011.
6. Bubley G, Carducci M, Dahut W. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate- pecific Antigen Working Group. J Clin Oncol, 1999, 17: 3461-3467.
7. Berry WR, Beer TM. Weekly docetaxel in the elderly, outcomes in men with androgen independent prostate cancer >70 vs < 70 years of age. Program and abstracts of the 39th Annual Meeting of the American Society of Clinical Oncology, May 31-3, 2003. Chicago, Illinois. Abstract, 2996.
8. Crawford DE, Rosenblum M, Ziada AM et all. Overview: hormone-refractory prostate cancer. Urology, 1999, 54(6A Suppl): 1-7.
9. Abrahamson Per-Anders. Revolutions in the management of hormone-refractory prostate cancer. European Urology Supplements, 2003, 2: 1-2.
10. Earhart RH. Docetaxel (Taxotere): preclinical and general clinical information. Semin Oncol, 1999, 26: 8-13.
Review
For citations:
GRITSKEVICH AA, MISHUGIN SV, TEPLOV AA, RUSAKOV IG. CLINICAL ASSESSMENT OF TAXANES IN THE FIRST-LINE CYTOTOXIC THERAPY OF CASTRATION-RESISTANT PROSTATE CANCER. Meditsinskiy sovet = Medical Council. 2016;(10):20-23. (In Russ.) https://doi.org/10.21518/2079-701X-2016-10-20-23
Views:
571
Email this article 